GENMOR-AI

AI-Powered Drug Discovery Based on Genetic Resilience

Accelerating Therapeutic Innovation Through Human Data and Machine Learning

Accelerating Therapeutic Innovation Through Human Data and Machine Learning At Halia Therapeutics, we’ve built a next-generation AI platform that’s reshaping precision medicine. GENMOR-AI (Genetic Modifier of Resilience – Artificial Intelligence) is our proprietary discovery engine that identifies protective genetic factors in people who remain healthy despite carrying high-risk mutations. These insights help us rapidly identify new drug targets — ones that have already been proven effective in humans.

What Is GENMOR-AI?

GENMOR-AI is an AI-driven drug discovery platform that analyzes genomic, clinical, and family-based data to reveal why some individuals never develop diseases despite being genetically predisposed.

The result: accelerated identification of resilience-based drug targets, validated by real-world health outcomes rather than hypothetical models.

GENMOR-AI Integrates:

Population-scale genomic sequencing

Linked medical records and family pedigree data

Advanced machine learning algorithms

Functional validation for therapeutic development

Why AI Drug Discovery Matters

Traditional drug discovery is slow, expensive, and prone to failure. GENMOR-AI flips the paradigm by starting with protective genetic variants that already prevent disease in humans.

This enables us to:

  1. Discover high-confidence therapeutic targets more quickly
  2. Reduce false positives and early-stage drug attrition
  3. Optimize hit-to-lead cycles using patient-centric data
  4. Deliver treatments grounded in biology that works

A Self-Improving System Built for Speed and Scale

GENMOR-AI operates on a continuous learning loop

As it processes more data, it refines its ability to:

  • Predict target validity and druggability

  • Prioritize targets with multi-disease relevance

  • Accelerate clinical translation timelines

It is this adaptive capability that positions GENMOR-AI as a competitive advantage in the precision medicine space.

Real-World Success Stories

GENMOR-AI is the foundation of Halia’s drug pipeline.

Each originated from a GENMOR-AI discovery grounded in human resilience.

Programs now in clinical and preclinical development include:

HT-4253 — Alzheimer’s prevention in APOE4 carriers, based on RAB10 suppression

HT-6184 — For MDS and obesity, targeting chronic inflammation via NEK7 and the NLRP3 inflammasome

HT-6283, HT-6515, and HT-6184 — Early-stage assets for neuroinflammation, dermatology, and ophthalmology

See the Pipeline

Broad Application Across Therapeutic Areas

GENMOR-AI supports discovery across diverse therapeutic categories:

  • Neurology – Alzheimer’s, neuroinflammation, and cognitive decline

  • Metabolism – Obesity, diabetes, NASH

  • Immunology & Inflammation – MDS, autoimmune disorders, dermatologic and ocular diseases

  • Oncology – Inflammation-driven tumor pathways

This versatility makes it a cornerstone of Halia’s scalable, disease-agnostic discovery engine.

The Future of AI Drug Discovery Is Human-Centered

GENMOR-AI isn’t just fast — it’s reliable, predictive, and patient-driven. By starting with real-world cases of disease resistance, we unlock the biology of protection and turn it into next-generation therapies.